ClinicalTrials.gg
RecruitingNCT07692165INT-210-II102Updated Jul 9, 2026

A Phase Ib/IIa Study of INT-210 Capsules in Participants With Active Ulcerative Colitis

A Phase 1/2 interventional study of INT-210 Capsule and INT-210 Capsule in Ulcerative Colitis (UC), sponsored by Innatus Therapeutics (Shanghai) Co., Ltd.. Recruiting at 15 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-09.

Sponsored by Innatus Therapeutics (Shanghai) Co., Ltd. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 184 studies in Colitis, Ulcerative with a site in China — 73 open to participants now, 96 under way, 25 of them phase 3. Colitis, Ulcerative · China.

Planned enrollment
125th of 136
24 · median 121
Started
2026
with 27 others
Phase 1/2
7 of 184
2 open now
Primary completion
2028-06
later than 70 of 95 live
Registered
172nd of 184
by date

Among the 184 studies in Colitis, Ulcerative with a site in China, this one is the 125th largest by planned enrollment of the 136 interventional ones that give a count, is one of 28 that started in 2026, is one of 7 in phase 1/2, reaches primary completion later than 70 of the 95 other live ones, and was the 172nd registered.

Colitis, Ulcerative

1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

73 of the 184 studies in Colitis, Ulcerative with a site in China are open now. Recruiting first, the newest first:

67 more — sign in →

All 73 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 184 studies in Colitis, Ulcerative with a site in China, or all of them as a file.
02

Study summary

A Multicenter, Randomized, Open-label Clinical Study to Evaluate the Safety and Efficacy of INT-210 Capsules in Participants with Active Ulcerative Colitis.

The study aims to evaluate the safety, efficacy, pharmacokinetic (PK) characteristics, pharmacodynamic (PD) characteristics of INT-210 in participants with active ulcerative colitis (UC).

03

Conditions studied

  • Ulcerative Colitis (UC)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily participate in the study and sign the form (ICF);
  2. Males or females aged ≥18 and ≤75 years at the time of signing the ICF;
  3. Diagnosed with UC for ≥3 months at the time of signing the ICF, with the diagnosis of UC supported by clinical manifestations and colonoscopy evidence, and confirmed by a histopathology report (pre-randomization colonoscopy and histopathology examination are acceptable as supporting evidence);
  4. Active UC, defined as: a modified Mayo score (including hematochezia, stool frequency, and endoscopy findings) of 4-9, with an endoscopy subscore of ≥2 (confirmed by central reading) and a hematochezia subscore of ≥1 in the Mayo score;
  5. At pre-randomization colonoscopy, the extent of UC lesions extends beyond the rectum (active disease ≥15 cm from the anal verge on colonoscopy, confirmed by central reading);
  6. Participants must have had an inadequate response or intolerance to at least one of the following UC treatments (inadequate response is defined as that the participant has previously discontinued the corresponding drug due to lack of efficacy as judged by the investigator; intolerance is defined as that the participant has previously discontinued the drug due to adverse reactions as judged by the investigator): oral sulfasalazine (SASP) and/or 5- aminosalicylate (5-ASA); oral ; azathioprine or 6- mercaptopurine; marketed anti-tumor necrosis factor-α (TNF-α) agents: infliximab or adalimumab, etc.; vedolizumab; marketed JAK inhibitors: tofacitinib, upadacitinib, etc.; marketed interleukin 12/23 (IL-12/23) inhibitors: ustekinumab, etc.; selective sphingosine-1-phosphate (S1P) receptor modulators: etrasimod, etc.; sulfasalazine (SASP) and/or 5- aminosalicylate (5-ASA); oral corticosteroids; azathioprine or 6- mercaptopurine; marketed anti-tumor necrosis factor-α (TNF-α) agents: infliximab or adalimumab, etc.; vedolizumab; marketed JAK inhibitors: tofacitinib, upadacitinib, etc.; marketed interleukin 12/23 (IL-12/23) inhibitors: ustekinumab, etc.; selective sphingosine-1-phosphate (S1P) receptor modulators: etrasimod, etc.;
  7. If participants are currently using the following drugs to treat UC, they must also meet the following requirements:

    • Glucocorticoid therapy: oral prednisone ≤20 mg/d (or equivalent drug dose) or budesonide ≤9 mg/d or beclomethasone ≤5 mg/d, with a stable dose for at least 2 weeks before the screening colonoscopy;
    • Aminosalicylate preparations: oral sulfasalazine and/or 5- aminosalicylate must be stable for at least ≥2 weeks before the screening colonoscopy and must remain stable during the study;
  8. Throughout the entire study period from the signing of the ICF and for 3 months after the last dose, female participants of and male participants who have not undergone vasectomy must comply with the specified requirements.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating women, or those planning to become pregnant during the study;
  2. Known allergy to any component of INT-210;
  3. Based on medical history and endoscopy and/or histological results, participants with suspected or confirmed Crohn's disease, unclassified colitis, acute fulminant colitis, toxic megacolon, intestinal perforation, microscopic colitis, ischemic colitis, or radiation colitis;
  4. Participants who have undergone surgery for UC or are planning surgery (including stoma creation, or total or partial proctectomy/colectomy, etc.);
  5. Evidence of unresected adenoma or dysplasia in the colon, including lowgrade or high-grade atypical hyperplasia, and unclassified atypical hyperplasia; presence of high-risk progressive adenoma, defined as:

    ① Adenoma diameter ≥10 mm; or ② Villous adenoma or mixed adenoma with villous structure exceeding 25%; or ③ Accompanied by high-grade intraepithelial neoplasia.

  6. With primary sclerosing cholangitis;
  7. History of alcohol or drug abuse or addiction within one year prior to screening;
  8. Have undergone other major surgery within 6 months prior to screening, or are planning surgery during the study; have a history of myocardial infarction, acute stroke or , thrombotic events such as deep vein thrombosis or pulmonary embolism, arrhythmia or unstable angina pectoris, coronary artery bypass grafting, or severe or pulmonale or pulmonary arterial hypertension that would affect the evaluation of study results, within 6 months prior to screening;
  9. Presence of clinically severe diseases, such as a history of cardiovascular, hepatic, endocrine, gastrointestinal, metabolic, neurological, pulmonary, or psychiatric diseases, or clinically significant diseases, conditions, or other evidence that the investigator considers would pose a risk to participant safety or interfere with the conduct, progress, or completion of the study;
  10. Have received two or more classes of biological products/small molecule targeted drugs (e.g., anti-TNF-α monoclonal antibodies, anti-integrin antibodies, anti-IL12/23 monoclonal antibodies, JAK inhibitors, S1P receptor modulators) and have been assessed by the investigator as treatment failure (UC disease progression requiring salvage therapy, inability to taper during the maintenance phase, or need for other effective therapies);
  11. Participants receiving the following drug therapies:

    • Use of non-steroidal anti-inflammatory drugs (excluding stable use of

      ≤100 mg/day aspirin for prevention of cardiovascular and cerebrovascular diseases and temporary use of ≤2000 mg/day acetaminophen for no more than three days for infectious pyrexia or mild to moderate pain), intestinal probiotics (including fecal transplant), fish oil, JAK inhibitors, immunoadsorption therapy, Chinese herbal medicines, or compound preparations containing Chinese herbal medicines within 2 weeks prior to randomization;

    • Use of azathioprine or 6-mercaptopurine, cyclosporine, thalidomide, methotrexate, mycophenolate, tacrolimus/sirolimus within 4 weeks prior to randomization;
    • Use of intravenous corticosteroids within 4 weeks prior to randomization, or rectal corticosteroids or rectal 5-ASA within 2 weeks prior to randomization;
    • Use of interferon or TNF-α inhibitors within 8 weeks prior to randomization;
    • Intravenous immunoglobulin injection or therapeutic plasma exchange within 8 weeks prior to randomization;
    • Use of S1P receptor modulators within 10 weeks prior to randomization;
    • Use of vedolizumab, IL-12/23 antibodies, cyclophosphamide, or chlorambucil within 12 weeks prior to randomization;
    • Use of leflunomide within 12 weeks prior to randomization, unless discontinued for 4 weeks before randomization and accelerated elimination (e.g., oral cholestyramine or activated charcoal) was completed at least 2 weeks prior to randomization, with corresponding medical history records required;
    • Use of rituximab within 1 year prior to randomization;
    • Use of any other or marketed products with effects within 8 weeks or 5 drug half-lives (whichever is longer) prior to randomization;
  12. Positive for Mycobacterium tuberculosis or judged by the investigator to have a potential M. tuberculosis infection, such as: positive T-SPOT.TB test or purified protein derivative (PPD) induration ≥5 mm (within 3 months prior to screening); chest imaging within 3 months prior to screening suggesting active tuberculosis infection lesions;
  13. History of recurrent invasive fungal infections or other chronic infections; herpes zoster or cytomegalovirus infection within 8 weeks prior to signing the ICF; clinically diagnosed clostridioides difficile infection or other intestinal infections within 30 days before the screening colonoscopy; positive clostridium test result during the screening period; infection requiring systemic anti-pathogen drugs (including antibacterial, antiviral, antifungal, anti-parasitic, etc.) for control within 7 days prior to randomization;
  14. Presence of any disease that may require treatment with systemic glucocorticoid during the study (e.g., moderate to severe asthma, dermatitis atopic, rheumatoid arthritis, etc.);
  15. Malignant tumors within 5 years prior to screening (except for adequately treated or resected basal cell or squamous cell skin cancer); or previous neoplasm screening that did not rule out tumor lesions;
  16. Participants with conditions that may affect the absorption of oral drugs, such as gastrectomy or clinically significant diabetes mellitus-related gastrointestinal diseases, or specific types of obesity surgery such as gastric bypass; participants who have only undergone simple gastric banding-like procedures that divide the stomach into separate pouches are not excluded;
  17. Participants who have undergone small intestine or colon operation and have evidence of colonic dysplasia or intestinal stenosis;
  18. Any of the following abnormalities in screening laboratory tests:

    • \<9 g/dL or white blood cells \<3.0×109/L or neutrophils \<1.5×109/L, \<100×109/L
    • Total (TBIL), (AST), or alanine transaminase (ALT) ≥1.5 times the (ULN)
    • Blood creatinine >1.5 times ULN
    • Any other abnormal laboratory test results that the investigator considers may expose the participant to unacceptable risks by participating in this study
    • Positive for surface antigen (HBsAg), or test results are HBsAg negative, hepatitis B core antibody (HBcAb) positive, and positive for hepatitis B virus deoxyribonucleic acid (HBV-DNA); positive for virus antibody (HCV-Ab) and positive for hepatitis C virus ribonucleic acid (HCV-RNA); positive for (HIV) antibody
    • Positive for intestinal pathogens (excluding colonizing microorganisms interpreted by the investigator to be non-pathogenic);
  19. Clinically significant abnormal during the screening period, which the investigator judges may increase the participant's safety risk;
  20. Have received any within 3 months prior to randomization or plan to receive any live vaccine during the clinical study;
  21. Participants whom the investigator considers have other factors that make them unsuitable for participation in this study.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    200 mg INT-210 capsule

    Drug: INT-210 Capsule

  • Experimental
    400 mg INT-210 capsule

    Drug: INT-210 Capsule

Interventions

  • DrugINT-210 Capsule

    All participants will receive oral treatment with INT-210 capsule 200 mg twice daily, starting from Day 1 (D1) of the treatment period (12 weeks).

  • DrugINT-210 Capsule

    All participants will receive oral treatment with INT-210 capsule 400 mg twice daily, starting from Day 1 (D1) of the treatment period (12 weeks)

06

What researchers measure

Primary outcomes

  1. The incidence of treatment-emergent adverse events

    Number of participants with treatment-related adverse events as assessed. The incidence of treatment-emergent adverse events will be measured using a combination of data collection methods, including tracking adverse events and assessing their onset or worsening relative to the initiation of treatment. The most recent version of the Medical Dictionary for Regulatory Activities (MedDRA) preferred terms will be used to classify adverse events, including their relationship to the treatment and maximum severity.

    Time frame: From enrollment through the safety follow-up visit on Day 92

  2. Treatment-emergent potentially clinically- significant abnormalities in safety laboratory parameters-hematology

    Time frame: From enrollment through the safety follow-up visit on Day 92

  3. Treatment-emergent potentially clinically significant abnormalities in safety laboratory parameters: blood chemistry

    Time frame: From enrollment through the safety follow-up visit on Day 92

  4. Treatment-emergent potentially clinically significant abnormalities in safety laboratory parameters: serum ferritin

    Time frame: From enrollment through the safety follow-up visit on Day 92

  5. Treatment-emergent potentially clinically significant abnormalities in safety laboratory parameters: coagulation

    Time frame: From enrollment through the safety follow-up visit on Day 92

  6. Treatment-emergent potentially clinically significant abnormalities in safety laboratory parameters: urinalysis

    Time frame: From enrollment through the safety follow-up visit on Day 92

  7. Treatment-emergent potentially clinically significant abnormalities in electrocardiogram values: QTcF (milliseconds)

    A standard 12-lead ECG will be used to collect ventricular rate, PR interval, QRS duration, QT interval, QTcF interval (Fridericia's correction), and ECG result description; the participant must rest for at least 5 minutes before the test. The investigator (or designated personnel) will clinically evaluate each 12-lead ECG.

    Time frame: From enrollment through the safety follow-up visit on 92

  8. Treatment-emergent potentially clinically significant abnormalities in vital signs: heart rate (beats per minute)

    Time frame: From enrollment through the safety follow-up visit on Day 92

  9. Treatment-emergent potentially clinically significant abnormalities in vital signs: blood pressure (mmHg)

    Time frame: From enrollment through the safety follow-up visit on Day 92

  10. Treatment-emergent potentially clinically significant abnormalities in vital signs: respiration rate (BPM)

    Time frame: From enrollment through the safety follow-up visit on Day 92

  11. Treatment-emergent potentially clinically significant abnormalities in vital signs: temperature (℃)

    Time frame: From enrollment through the safety follow-up visit on Day 92

Secondary outcomes

  1. Pharmacokinetics parameter: Cmax of INT-210

    Maximum observed plasma concentration

    Time frame: From Day 1 to Day 85

  2. Pharmacokinetics parameter: Cmax_ss of INT-210

    Peak Steady-state Concentration

    Time frame: rom Day 1 to Day 85

  3. Pharmacokinetics parameter: Cmin_ss of INT-210

    Trough Steady-state Concentration

    Time frame: From Day 1 to Day 85

  4. Pharmacokinetics parameter: Cave_ss of INT-210

    Average Steady-state Blood Drug Level

    Time frame: From Day 1 to Day 85

  5. Pharmacokinetics parameter: AUC0-inf of INT-210

    Area under the curve from time 0 extrapolated to infinite time (AUCinf) of INT-210

    Time frame: From Day1 to Day 85

  6. Pharmacokinetics parameter: AUC0-t of INT-210

    Area Under the Plasma Drug concentration-time Curve from Time 0 to the Last Measurement

    Time frame: From Day 1 to Day 85

  7. Pharmacokinetics parameter: AUCss

    Area Under the Steady-state Blood drug Concentration-time Curve

    Time frame: From Day 1 to Day 85

  8. Pharmacokinetics parameter: Tmax of INT-210

    Time of maximum observed concentration (Tmax)

    Time frame: From Day 1 to Day 85

  9. Pharmacokinetics parameter: T1/2 of INT-210

    Half-life (T1/2) (hours)

    Time frame: From Day 1 to Day 85

  10. Pharmacokinetics parameter: CL/F of INT-210

    Apparent Plasma Clearance

    Time frame: From Day 1 to Day 85

  11. Pharmacokinetics parameter: Kel of INT-210

    Elimination Rate Constant

    Time frame: From Day 1 to Day 85

  12. Pharmacokinetics parameter: MRT of INT-210

    Mean Residence Time

    Time frame: From Day1 to Day 85

  13. Pharmacokinetics parameter: Vz/F of INT-210

    Apparent Volume of Distribution

    Time frame: From Day 1 to Day 85

  14. Pharmacokinetics parameter: DF of INT-210

    Degree of Fluctuation

    Time frame: From Day 1 to Day 85

  15. Pharmacokinetics parameter: RAAUC0-t of INT-210

    Accumulation Ratio Calculated Based on AUC

    Time frame: From Day 1 to Day 85

  16. Pharmacokinetics parameter: RACmax of INT-210

    Accumulation Ratio Calculated Based on Cmax

    Time frame: From Day 1 to Day 85

  17. Clinical Remission Rate

    The modified Mayo score (MMS) is uesd for assessing the disease activity of UC, including the Rectal Bleeding Subscore (RBS), Stool Frequency Subscore (SFS), and Endoscopy Subscore (ES). The score for each sub-item ranges from 0-3, and the total MMS score ranges from 0-9. A higher score indicates more severe disease, and the total score is a comprehensive assessment of active UC. The percentage of participants who, after taking INT-210, achieve a modified Mayo score ≤2, with an ES ≤1 (excluding "friability" assessment), RBS=0, SFS≤1, and with no increase from baseline in the above 3 subscores.

    Time frame: From Day 0 to Day 85

  18. Clinical Response Rate

    The percentage of participants who, after taking INT-210, have a decrease in their modified Mayo score of ≥2 points and ≥30% from baseline, and a decrease in RBS of ≥1 point or an absolute RBS of ≤1

    Time frame: From Day 0 to Day 85

  19. Endoscopic Remission Rate

    The percentage of participants who, after taking INT-210, have an ES ≤1 (excluding "friability" assessment)

    Time frame: From Day 0 to Day 85

  20. Histological Improvement Rate

    The percentage of participants who, after taking INT-210, achieve a Geboes Index Score (GS) ≤3.1, and an ES=0/1 in the MMS (excluding "friability" assessment).

    Time frame: From Day 0 to Day 85

  21. Mucosal Healing Rate

    The percentage of participants who, after taking INT-210, have a GS ≤2B.1

    Time frame: From Day 0 to Day 85

  22. Symptomatic Remission Rate

    The percentage of participants who, after taking INT-210, have an SFS = 0/1 and an RBS = 0.

    Time frame: From Day 0 to Day 85

07

Study locations

15 of 15 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Jun 2028, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2026
First posted
Jul 9, 2026
StartActual
Jun 11, 2026
Primary completionEst.
Jun 2028
CompletionEst.
Jun 2028
Last update
Jul 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07692165
Lead sponsor
Innatus Therapeutics (Shanghai) Co., Ltd.
Responsible party
Sponsor
First posted
Jul 9, 2026
Start date
Jun 11, 2026
Primary completion
Jun 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Jul 9, 2026

Study contacts

Iris Liu
Contact
irisliu@innatustherapeutics.com
+86 010-82089858
Minhu Chen
principal investigator · First Affiliated Hospital, Sun Yat-Sen University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion